Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Infinity Pharmaceuticals Inc (NASDAQ:INFI)

1.92
Delayed Data
As of Apr 21
 -0.05 / -2.54%
Today’s Change
0.84
Today|||52-Week Range
6.63
+42.22%
Year-to-Date
AbbVie (ABBV) Presents Positive Data on HCV Combination Drug
Apr 21 / Zacks.com - Paid Partner Content
Infinity Pharmaceuticals (INFI) Looks Good: Stock Jumps 19%
Apr 18 / Zacks.com - Paid Partner Content
Nivalis' (NVLS) Shares Down After Merger Deal with Alpine
Apr 20 / Zacks.com - Paid Partner Content
Bio-Path Holdings (BPTH) Looks Good: Stock Moves 13% Higher
Apr 17 / Zacks.com - Paid Partner Content
Ultragenyx's Hypophosphatemia Drug Succeeds in Phase III
Apr 19 / Zacks.com - Paid Partner Content
Should You Retain Universal Health (UHS) Stock in Portfolio?
Apr 12 / Zacks.com - Paid Partner Content
Why Is Infinity (INFI) Down 37.4% Since the Last Earnings Report?
Apr 19 / Zacks.com - Paid Partner Content
Here's Why You Should Dump Tenet Healthcare (THC) Stock Now
Apr 10 / Zacks.com - Paid Partner Content
AMAG Files for FDA Approval of Subcutaneous Form of Makena
Apr 18 / Zacks.com - Paid Partner Content
Infinity Pharmaceuticals Focuses on Lead Candidate IPI-549
Apr 10 / Zacks.com - Paid Partner Content

Today’s Trading

Previous close1.97
Today’s open1.95
Day’s range1.88 - 2.01
Volume683,425
Average volume (3 months)1,138,771
Market cap$96.8M
Dividend yield--
Data as of 3:59pm ET, 04/21/2017

Growth & Valuation

Earnings growth (last year)+76.72%
Earnings growth (this year)--
Earnings growth (next 5 years)+101.00%
Revenue growth (last year)-82.83%
P/E ratioNM
Price/Sales3.58
Price/Book1.17

Competitors

 Today’s
change
Today’s
% change
OPHTOphthotech Corp-0.04-1.44%
CPIXCumberland Pharmaceu...-0.31-4.96%
AGLEAeglea Bio Therapeut...+0.14+2.03%
--Innovative Pharmaceu...-0.00-1.45%
Data as of 3:59pm ET, 04/21/2017

Financials

Next reporting dateMay 9, 2017
EPS forecast (this quarter)-$0.27
Annual revenue (last year)$18.7M
Annual profit (last year)-$30.1M
Net profit margin-160.77%

Profile

Sector
Health Technology
Industry
Biotechnology
Chairman &
Chief Executive Officer
Adelene Q. Perkins
President, EVP, Chief Financial &
Business Officer
Lawrence E. Bloch
Corporate headquarters
Cambridge, Massachusetts

Forecasts


Search for Jobs